In a filing, Nektar Therapeutics revealed its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $7177.0 on May 19 ’25. In the deal valued at $0.67 per share,10,712 shares were sold. As a result of this transaction, Zalevsky Jonathan now holds 305,892 shares worth roughly $7.65 million.
Then, Wilson Mark Andrew sold 9,996 shares, generating $6,697 in total proceeds. Upon selling the shares at $0.67, the Chief Legal Officer now owns 314,296 shares.
Before that, ROBIN HOWARD W sold 23,208 shares. Nektar Therapeutics shares valued at $15,549 were divested by the President & CEO at a price of $0.67 per share. As a result of the transaction, ROBIN HOWARD W now holds 1,063,693 shares, worth roughly $26.6 million.
H.C. Wainwright reiterated its Nektar Therapeutics [NKTR] rating to a Buy in a research note published on June 24, 2025; the price target was $120. A number of analysts have revised their coverage, including BTIG Research’s analysts, who remained covering the stock and in late June has reiterated a ‘”a Buy”‘ rating for it. Jefferies also remained covering NKTR and has increased its forecast on April 11, 2025 with a “Buy” recommendation from previously “Hold” rating. Oppenheimer revised its rating on March 14, 2025. It rated NKTR as “an Outperform” which previously was an “a Perform”.
Price Performance Review of NKTR
On Friday, Nektar Therapeutics [NASDAQ:NKTR] saw its stock fall -0.36% to $25.01. Over the last five days, the stock has gained 1.01%. Nektar Therapeutics shares have risen nearly 35.56% since the year began. Nevertheless, the stocks have risen 79.28% over the past one year. While a 52-week high of $37.38 was reached on 06/25/25, a 52-week low of $6.48 was recorded on 04/09/25.
Levels Of Support And Resistance For NKTR Stock
The 24-hour chart illustrates a support level at 23.82, which if violated will result in even more drops to 22.62. On the upside, there is a resistance level at 26.25. A further resistance level may holdings at 27.48.
How much short interest is there in Nektar Therapeutics?
A steep rise in short interest was recorded in Nektar Therapeutics stocks on 2025-06-13, dropping by -0.11 million shares to a total of 0.6 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 0.71 million shares. There was a decline of -19.3%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 08, 2025 when B. Riley Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $4 price target.
